[The influence of gastroesophageal reflux on the course and therapy of bronchial asthma].
The epidemiological and clinical data suggest the influence of gastroesophageal reflux disease (GER) on the course of bronchial asthma (BA). Pathogenetic relationships of both diseases are still not clear. The most possible theory seems to be micro-aspirations of refluxing digestive contents leading to the development of bronchial inflammation. It is increasingly improved the benefits of treatment for gastroesophageal reflux on asthma course. Apart from advices referring proper diet and resting with semirecumbent position, the most effective method of treatment seems to be appropriately high dose of proton pump inhibitors. It is seamed that in some cases an important role in development of GER could play hypotention produced in mediastinum in patients with exacerbated course of asthma. It is suggested to connect treatment of both illnesses to benefit in clinical course of GER and BA as well.
Samoliński
Bolesław
B
Akademia Medyczna w Warszawie, Zakład Profilaktyki Zagrozeń Srodowiskowych Wydziału Nauki o Zdrowiu. bsamol@amwaw.edu.pl
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001249:Asthma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D009853:Omeprazole / Q000627:therapeutic use; D054328:Proton Pump Inhibitors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D009853:Omeprazole